Antidepressant Discontinuation Syndrome: A Psychiatrist’s Guide to Coming Off SSRIs and SNRIs

The standard antidepressant taper instructions look the same across most clinics. Cut the dose in half for two weeks, then stop. Maybe three weeks for the cautious prescriber. Six weeks if the patient pushes back.

For most people who’ve been on an SSRI or SNRI longer than six months, that schedule predictably fails. The first few weeks feel manageable. Then somewhere around day 10 to 21, the symptoms start. Dizziness on standing. Brain zaps when the eyes move. GI upset. Sleep disruption. A wave of anxiety that doesn’t match anything happening in life. The prescriber, when called, often says the depression is coming back and recommends restarting the medication.

Often, those symptoms are antidepressant discontinuation syndrome, and the taper schedule is what produced them.

The federal government weighed in on this in May 2026. See our read on the MAHA psychiatric overprescribing plan and what it changes for adults coming off antidepressants.

I’m a board-certified psychiatrist with subspecialty board certification in forensic psychiatry, running a cash-pay telehealth practice in North Carolina. Patients land in my practice every month asking how to come off an antidepressant they’ve been on for years. Some are doing it because the medication never worked. Some because side effects accumulated. Some because long-term concerns about cognition, sexual function, or weight became hard to ignore. Some because they feel ready to try without it. The common thread is that previous taper attempts failed, often badly, because the schedule they were given didn’t account for how serotonin transporter occupancy actually changes with dose.

When weight gain during antidepressant treatment becomes its own clinical problem, it can be treated directly; see whether a psychiatrist can prescribe weight loss medication.

This article lays out what discontinuation syndrome is, why standard tapers fail, what the hyperbolic taper method does differently, how to tell withdrawal from relapse, which antidepressants are the hardest to stop, what supervised tapering involves, and how the current literature has reshaped clinical practice. It’s written for adults on long-term SSRI or SNRI treatment considering coming off, for patients in the middle of a failed taper trying to make sense of what’s happening, and for clinicians wanting a current read on a literature that’s shifted considerably in the last six years.

Deciding whether to stay on, switch, or stop a medication is part of the bigger picture. Our guide to depression treatment in North Carolina covers how depression is evaluated and treated end to end.

What Antidepressant Discontinuation Syndrome Actually Is

Antidepressant discontinuation syndrome is the constellation of physical and psychological symptoms that emerges when an SSRI or SNRI is stopped or reduced too quickly. It’s listed in DSM-5 under medication-induced disorders, and it has been part of the psychiatric literature for decades, though the field has only recently come to terms with how severe and prolonged it can be.

For decades, the working assumption in psychiatry was that these symptoms were mild and self-limiting, typically resolving within one to two weeks. That framing came from short-duration clinical trials, most funded by manufacturers, that under-counted withdrawal symptoms and under-represented long-term users.

The 2019 meta-analysis by Davies and Read reset that conversation. Their systematic review covered 24 studies. In the 14 that measured incidence, roughly 56% of people coming off antidepressants had withdrawal symptoms. In 4 large studies that rated severity, nearly half of those affected chose the most severe rating on offer (Davies & Read, 2019). Duration varied widely. Many studies showed symptoms persisting for several weeks; some patients reported symptoms lasting months or longer. The mild and brief framing didn’t survive the data.

The Royal College of Psychiatrists revised its position statement on antidepressants in 2019, formally acknowledging that withdrawal can be severe and prolonged. NICE updated its depression guideline (NG222) in 2022 to recommend slow, individualized tapering. The Maudsley Deprescribing Guidelines, published in 2024 by Horowitz and Taylor through Wiley, formalized the hyperbolic taper as the contemporary standard for SSRI and SNRI discontinuation (Horowitz & Taylor, 2024).

What hasn’t fully changed is what most patients are told at the prescriber’s office. That gap is the reason this article exists.

The Symptoms: What Withdrawal Looks Like in Real Time

The symptom cluster has been organized using the FINISH mnemonic: Flu-like symptoms, Insomnia (often with vivid dreams), Nausea, Imbalance, Sensory disturbances, and Hyperarousal. That covers the territory, but the lived experience is more textured than a list suggests.

The sensory disturbances are the most distinctive sign. Patients describe “brain zaps,” brief shock-like sensations that often coincide with eye movement. The mechanism is thought to involve abrupt changes in serotonergic modulation of vestibular and visual integration circuits, though the exact pathway is incompletely characterized. Brain zaps are not dangerous, but they’re disorienting and unmistakable to anyone who’s had them.

Dizziness is often the next most-cited symptom. It tends to be position-related, worse on standing or with rapid head movements. The flu-like malaise can include headache, muscle aches, low-grade chills, and the kind of bone-deep fatigue that doesn’t respond to rest. GI symptoms range from nausea to cramping to changes in bowel pattern.

The psychological symptoms are what gets misread. Anxiety surges can be intense and seemingly unprovoked. Crying spells that don’t track to anything in life. Irritability. Mood lability. Some patients describe a sense of emotional rawness, an exposure to feeling that didn’t exist while medicated. This is the cluster most often mistaken for depression recurrence, and the misreading drives the most common clinical mistake in tapering: pulling the patient back to the original dose and concluding the medication was needed all along.

Timing matters for the differential. Discontinuation symptoms typically emerge within 24 to 72 hours of a dose drop for short-half-life agents (paroxetine, venlafaxine), within 2 to 7 days for medium-half-life agents (sertraline, citalopram, escitalopram), and within 1 to 3 weeks for fluoxetine because of its long-half-life active metabolite. Peak severity usually falls within the first two weeks after the drop. Duration varies. For most patients, acute symptoms resolve within two to six weeks. A meaningful subset experiences protracted symptoms lasting months, sometimes longer, described in the literature as persistent post-withdrawal disorder (Cosci & Chouinard, 2020).

For the smaller group whose symptoms run for months, see our guide to post-acute withdrawal syndrome, which explains how protracted antidepressant withdrawal is told apart from relapse.

For patients whose anxiety has been a dominant symptom across their treatment course, the differential between discontinuation-driven anxiety and underlying anxiety is its own clinical question, and one that comes up regularly with patients seeking anxiety care across North Carolina.

Why Standard 2-to-4-Week Tapers Fail

The core reason standard tapers fail is pharmacokinetic. Serotonin transporter (SERT) occupancy does not scale linearly with dose. The dose-occupancy curve is hyperbolic, with diminishing returns at the top and accelerating drop-off at the bottom.

The numbers, using citalopram as the worked example: at 40 mg daily, SERT occupancy sits around 85%. At 20 mg, occupancy drops to roughly 80%. At 10 mg, it’s about 71%. At 5 mg, 58%. At 2 mg, around 38%. At 1 mg, somewhere near 25%. Halving the dose from 40 mg to 20 mg costs about 5 percentage points of receptor occupancy. Halving from 2 mg to 1 mg costs 10 to 15 points. The biology of withdrawal scales with the change in occupancy, not the change in milligrams.

What this means in practice: a taper that cuts the dose by 50% every two weeks delivers small physiologic changes at the top of the curve and progressively larger ones at the bottom. The patient often feels fine for the first two or three steps, then crashes at the final steps. That crash gets misread as relapse and the taper gets abandoned.

Horowitz and Taylor’s 2019 Lancet Psychiatry paper laid out this argument formally and proposed an alternative: tapers should follow the inverse of the hyperbolic occupancy curve, with proportionally smaller dose reductions at lower doses (Horowitz & Taylor, 2019). The dose steps at the bottom often end up well below the smallest commercially available tablet size, which is why liquid formulations and compounded microdoses are central to doing this well.

Sertraline is the one where that logistics question has a clean answer and a hidden catch, which our guide to Zoloft withdrawal works through.

Kindling is the other concern. Repeated cycles of rapid taper, withdrawal, and reinstatement may sensitize the central nervous system over time, producing more severe withdrawal on each subsequent attempt. The data here are less developed than the occupancy-curve evidence, but the clinical experience is consistent enough that contemporary deprescribing guidelines now counsel against pushing through severe withdrawal symptoms on a planned-out fast schedule.

The Hyperbolic Taper Method and the Science Behind It

The hyperbolic taper method, formalized by Horowitz and Taylor and adopted in the Maudsley Deprescribing Guidelines, follows three principles.

First, dose reductions are proportional to current dose, not arithmetic. Instead of cutting a fixed number of milligrams at each step, Horowitz and Taylor size each cut by its effect on transporter occupancy: about 10 percentage points per step, or 5 for a more cautious taper (Horowitz & Taylor, 2019). For citalopram, that works out to 20 mg, then 9.1 mg, then 5.4 mg, and on down to about 0.4 mg before the final stop. Each step is sized to produce roughly equal occupancy changes, which the patient experiences as roughly equal levels of withdrawal pressure across the taper. NICE’s 2022 guideline puts the same idea in plainer terms: each step is a proportion of the previous dose, such as 50%, with smaller cuts, such as 25%, as the dose gets lower (NICE, 2022).

Second, dose changes happen at intervals long enough for the system to stabilize. Horowitz and Taylor suggest allowing about 4 weeks after each reduction, long enough to catch withdrawal effects that show up late (Horowitz & Taylor, 2019). Cutting again sooner risks stacking the next reduction on top of a reaction that hasn’t surfaced yet.

Third, the taper is symptom-paced, not calendar-paced. If a patient develops moderate withdrawal symptoms after a step, the next reduction waits until the system has restabilized (NICE, 2022). In one paroxetine study Horowitz and Taylor reviewed, tapers fitted to each patient averaged about 9 months, and the longest ran almost 4 years (Horowitz & Taylor, 2019). The duration is driven by the patient’s response, not by an arbitrary schedule.

Doing this practically requires access to non-standard dose forms. Many SSRIs are available as oral solutions: sertraline (20 mg/mL), citalopram (10 mg per 5 mL), escitalopram (5 mg per 5 mL), fluoxetine (20 mg per 5 mL), and paroxetine (10 mg per 5 mL). These let a patient draw up arbitrary doses with an oral syringe. For SNRIs without liquid formulations, including venlafaxine and duloxetine, the options are counting beads from extended-release capsules (well-documented for venlafaxine), opening capsules and weighing portions, or working with a compounding pharmacy to produce custom-dose capsules.

Duloxetine is a harder case than that. Its label rules out opening the capsule at all, which takes bead counting off the table. Our guide to Cymbalta withdrawal covers the routes that remain.

The Maudsley Deprescribing Guidelines (Horowitz and Taylor, Wiley 2024) contain medication-specific taper schedules for the major SSRIs and SNRIs, the other common antidepressants, and benzodiazepines, Z-drugs, and gabapentinoids. They’re the most current practical reference, and worth a clinician’s time.

Withdrawal Versus Relapse: How to Tell the Difference

This is the differential that drives more taper failures than any other. The standard advice given to patients, that withdrawal lasts one to two weeks and anything beyond that is depression recurrence, has been the clinical default and is wrong often enough to be dangerous.

Several criteria help separate the two.

Timing relative to the dose change. Discontinuation symptoms emerge within days to a few weeks after a dose reduction. Depression recurrence more commonly emerges weeks to months after stopping, often preceded by a period of stability.

Symptom character. Discontinuation produces a distinctive somatic and sensory cluster: brain zaps, dizziness, GI symptoms, flu-like malaise, vivid dreams. Depression recurrence centers on cognitive and affective changes: persistent low mood, anhedonia, hopelessness, suicidal ideation, sleep changes without the sensory disturbances. Anxiety can show up in both, which is part of why this differential gets botched.

Symptom evolution. Discontinuation symptoms tend to peak within the first two weeks after a dose drop and then improve, sometimes slowly. Depression recurrence tends to deepen over time without intervention.

Response to dose. The clearest diagnostic test is reinstating a partial dose. If symptoms resolve within 24 to 72 hours of resuming the antidepressant, they were almost certainly withdrawal. If symptoms persist for two to four weeks after restoring the dose, depression recurrence is the more likely explanation.

For patients whose depression never fully responded to the antidepressant in the first place, the differential carries extra weight. Coming off a medication that wasn’t doing the work can produce withdrawal that gets misattributed to “the medication was helping after all.” The clinical question to keep front of mind: was this medication doing the work it claimed to do, or were symptoms simply suppressed by serotonergic tone, with the underlying drivers untouched?

This is where the cross-axis question matters. A meaningful fraction of patients diagnosed with treatment-resistant depression have hormonal, thyroid, metabolic, or sleep-related contributors that were never tested. For men in particular, low testosterone, subclinical hypothyroidism, and insulin resistance can produce a clinical picture indistinguishable from atypical depression. The companion piece on hormonal contributors to mood lays out what a hormone-informed psychiatric workup looks like, and the testosterone side of that workup is covered in more detail in TRT in Wilmington NC. When tapering off an antidepressant exposes underlying contributors that weren’t addressed, the next step is to identify and treat what was actually driving the symptoms, not to restart the SSRI by default.

Which Antidepressants Are Hardest to Stop

Withdrawal severity tracks pharmacokinetics. Two factors dominate: half-life and receptor binding profile.

Paroxetine is the worst SSRI for withdrawal. Half-life is about 21 hours, with no clinically meaningful active metabolite. Add its anticholinergic activity and its short receptor dwell time, and you get the most aggressive withdrawal profile in the SSRI class. Patients on paroxetine who miss even a single dose often describe symptoms within 24 hours.

Paroxetine is hard enough to stop that it gets its own guide. For the drug-specific version, including why the gut symptoms hit and how to taper Paxil with the liquid form, see how to taper off paroxetine.

Venlafaxine is the worst SNRI, and arguably the worst antidepressant in common use for withdrawal. The parent compound has a half-life around 5 hours; its active metabolite, O-desmethylvenlafaxine, sits around 11 hours. The combination produces unstable serum levels and rapid receptor unbinding when doses are missed or reduced. Patients on venlafaxine commonly describe severe withdrawal within hours of a missed dose.

Venlafaxine is hard enough to stop that it gets its own guide. For the drug-specific picture, including why withdrawal hits between doses and how to taper Effexor without crashing, see venlafaxine withdrawal.

Duloxetine has a half-life around 12 hours and a withdrawal profile that’s also significant, though typically less severe than venlafaxine. The lack of an extended-release liquid formulation and the practical difficulty of bead-counting capsules make tapering harder logistically.

Sertraline (half-life about 26 hours), citalopram (about 35 hours), and escitalopram (27 to 32 hours) sit in the middle (FDA Zoloft, Celexa, and Lexapro prescribing information). Withdrawal is real but slower-onset, and often less severe step-for-step than paroxetine or venlafaxine.

Fluoxetine is the gentlest. Its parent compound has a half-life of 1 to 3 days, and its active metabolite norfluoxetine has a half-life of 7 to 15 days. The pharmacokinetics produce a built-in slow taper after stopping. Some clinicians use a “fluoxetine bridge,” cross-titrating from paroxetine or venlafaxine to fluoxetine and then tapering fluoxetine, specifically to take advantage of this property. The strategy has clinical literature behind it, but it’s not a universal solution and works best for patients whose primary issue is short-half-life withdrawal from the original agent.

Fluoxetine’s long half-life makes it the easiest antidepressant to stop and the basis of the bridge strategy. For the drug-specific picture, see our guide on how to taper off fluoxetine.

Mirtazapine, bupropion, vilazodone, and vortioxetine each have their own withdrawal profiles, generally milder than the SNRIs but variable across patients. Trazodone is rarely associated with significant withdrawal at the doses commonly used for sleep.

What Supervised Tapering Looks Like in NC

Supervised tapering is highly individualized. The variables that drive taper design are too patient-specific for a single protocol: duration on the medication, history of prior taper attempts, severity of original symptoms, concurrent medical conditions, hormonal status, sleep, life stressors, support resources, and clinical response in real time. The plan is built around the patient.

What supervision provides, that a do-it-yourself taper can’t, is the infrastructure to make taper decisions clinically rather than by guesswork.

Real-time adjustment matters. When a patient experiences moderate withdrawal symptoms three weeks into a step, the clinical decision tree includes options most patients can’t navigate alone: wait, partially reinstate, slow the next step, switch formulation, add adjunctive symptom relief, evaluate for differential diagnoses that have become more visible as the antidepressant load drops. Each option has tradeoffs. None of them follow a template.

Compounding pharmacy access matters. Many of the dose steps at the bottom of a hyperbolic taper fall below the smallest commercially available tablet. Liquid formulations help for the SSRIs that have them. For everything else, including most of the SNRIs and older agents, custom-dose capsules from a compounding pharmacy are the practical solution. Patients without a clinician orchestrating this often default to splitting tablets, which works for the larger doses but produces unreliable subtherapeutic dosing at the bottom.

Cross-axis assessment matters. A taper sometimes reveals underlying contributors that the antidepressant was masking: hormonal abnormalities, thyroid dysfunction, sleep disorders, metabolic syndrome, undiagnosed ADHD, ongoing trauma exposure. The hormones piece is especially common in men whose original presentation was atypical depression. When cognitive complaints persist beyond the acute withdrawal window, the broader workup can include peptide options for cognition and mood, with the caveat that evidence in the post-discontinuation context specifically is preliminary. When a patient’s symptoms shift during taper in a way that doesn’t fit either withdrawal or relapse, a broader workup belongs in the plan.

Symptom validation matters. Many patients have been told their withdrawal symptoms are psychosomatic, drug-seeking, or proof that the medication was needed. Validation from a clinician who recognizes the syndrome accelerates recovery in ways that purely pharmacologic interventions can’t.

Baghel Psychiatry runs as a cash-pay telehealth practice serving patients across North Carolina. The clinical model is a $250/month flat membership covering psychiatry and ongoing management; labs and medications are paid separately. There’s one price and no tiers, billed month to month with no contract. The model exists because comprehensive longitudinal care across a 6 to 18 month taper doesn’t fit insurance authorization patterns.

If you’re considering coming off an antidepressant, or you’ve attempted a taper that didn’t work, book a consultation to work out what an appropriate plan looks like for your situation.

The Henssler Controversy: How Big Is This Problem, Really

The literature on antidepressant withdrawal has had its share of revisions, and the most recent fight is worth describing honestly. In June 2024, Henssler and colleagues published a systematic review and meta-analysis in Lancet Psychiatry that arrived at substantially lower incidence estimates than the Davies and Read 2019 paper. In the drug groups, 31% reported discontinuation symptoms against 17% on placebo, and 2.8% reported severe symptoms against 0.6%. The authors put the rate attributable to the drug itself at roughly 15% (Henssler et al., 2024).

The reaction was immediate. Critics pointed out several methodological concerns. The Henssler dataset relied heavily on placebo-controlled discontinuation trials, which under-represent long-term users (most participants had been on antidepressants for under a year). The studies included used variable definitions of withdrawal, some of which excluded symptoms that the broader clinical literature treats as core features of the syndrome. Spontaneous reporting was used in many studies rather than systematic symptom-checklist assessment, which under-counts symptoms patients don’t think to mention.

The Davies and Read 2019 paper had its own methodological criticisms when it came out. The included studies were heterogeneous. Some were patient surveys rather than prospective trials. Selection bias likely inflated estimates: patients with bad withdrawal experiences are more motivated to participate in surveys.

The honest read is that both papers tell part of the story. Withdrawal incidence is probably lower in short-duration randomized trials and probably higher in long-duration real-world samples. Severity is probably overrepresented in patient surveys and underrepresented in trial-based meta-analyses. The clinical reality with patients who’ve been on SSRIs for five, ten, or fifteen years tracks closer to the Davies and Read picture than to the Henssler picture, which is consistent with the population-level signal that long-term users are at higher risk.

What the controversy doesn’t change is the clinical recommendation. Slow, hyperbolic, symptom-paced tapering is appropriate regardless of which incidence estimate is closer to the population mean, because the patients who do experience severe withdrawal aren’t a marginal subset, and the cost of getting it wrong (months of suffering, restart of medications that weren’t needed, lasting loss of trust in psychiatric care) is too high.

A Brief Note on PSSD and Persistent Sexual Symptoms

Post-SSRI sexual dysfunction (PSSD) is a related but separate clinical entity that deserves brief mention here. PSSD refers to sexual side effects that begin during SSRI or SNRI treatment and persist after the medication is stopped. Symptoms can include genital numbness, loss of libido, anorgasmia, and erectile changes that don’t resolve with discontinuation.

For the full picture, including the proposed diagnostic criteria, what regulators in Europe and Canada concluded, and how an honest workup rules out treatable causes, see our guide to post-SSRI sexual dysfunction.

The condition was historically dismissed as coincidental, psychogenic, or attributable to underlying depression. That position has shifted in the regulatory literature. In 2019, the European Medicines Agency required labeling updates on SSRIs to mention persistent sexual dysfunction after discontinuation. Health Canada issued similar guidance in 2021. The FDA has acknowledged the issue in a more limited way and has not mandated US label changes on the same scale.

Mechanism is incompletely characterized. Hypotheses include downstream effects on dopaminergic tone, glutamatergic signaling, genital nitric oxide pathways, and possible epigenetic changes that persist after the medication is cleared. None of these are firmly established.

For patients with persistent sexual symptoms after stopping an SSRI or SNRI, the differential includes PSSD, untreated depression, hormonal contributors (in men, low testosterone is common), psychological factors, and primary sexual disorders. A workup that includes total and free testosterone, prolactin, thyroid panel, and a basic psychiatric and relationship assessment belongs in the plan. PSSD is a diagnosis of exclusion at this point in the literature, and the management is unsatisfying because no treatment has clear evidence behind it.

For this hub piece, the relevant point is that persistent sexual symptoms after antidepressant discontinuation are real, increasingly recognized in the regulatory literature, and worth raising with a clinician rather than dismissing.

Frequently Asked Questions

How long does antidepressant withdrawal last?

Acute withdrawal typically resolves within two to six weeks for most patients on a properly paced taper. A meaningful subset experiences protracted symptoms lasting several months, and a smaller subset develops persistent post-withdrawal disorder (Cosci & Chouinard, 2020). Case reports describe symptoms lasting a year or longer (Horowitz & Taylor, 2019). Duration tracks how long the patient was on the medication, which agent it was, and how aggressive the taper was. Patients on paroxetine or venlafaxine for many years are at the highest end of the duration distribution.

Are brain zaps dangerous?

Brain zaps are not dangerous in the sense of producing physical injury, but they are a real neurological symptom and they correlate with the rate of dose change. If brain zaps are intense or persistent, the appropriate response is to slow the taper or partially reinstate the previous dose, not to power through.

Can I switch to fluoxetine to make tapering easier?

The fluoxetine bridge strategy has clinical literature behind it and can help for short-half-life agents like paroxetine and venlafaxine. It’s not universally appropriate, and the cross-titration adds its own complexity. A clinician familiar with the strategy can assess whether it fits your situation. Self-managed fluoxetine bridging is generally not advisable because the cross-titration timing matters.

How do I tell if it’s withdrawal or my depression coming back?

Four factors usually clarify the picture: timing relative to dose change (withdrawal within days, relapse over weeks to months), symptom character (somatic and sensory in withdrawal, cognitive and affective in relapse), evolution (withdrawal peaks then improves, relapse deepens), and response to a partial dose reinstatement (rapid resolution in withdrawal, slow or absent response in relapse). When the differential isn’t clear, a clinician can help structure a reinstate-and-observe approach to distinguish them.

Can I taper without a doctor?

Some patients on shorter-duration treatment with lower-risk agents can taper successfully on their own with a slow, symptom-paced schedule. Patients on long-duration paroxetine, venlafaxine, or duloxetine, or anyone with a prior failed taper, are at higher risk for severe withdrawal and benefit from clinical support. The compounding-pharmacy access and real-time symptom management infrastructure that supervised tapering provides is hard to replicate without a clinician involved.

Will I need to restart the medication if withdrawal gets bad?

Partial reinstatement is a common and appropriate response to severe withdrawal, and it doesn’t represent failure. The standard approach is to step back to the prior tolerated dose, allow the system to restabilize for several weeks, then resume the taper at a slower pace with smaller dose steps. Many successful tapers include one or more reinstatement steps along the way.

Does insurance cover supervised tapering?

Baghel Psychiatry is a cash-pay practice and does not bill insurance. PPO and POS patients can submit a superbill for potential out-of-network reimbursement; coverage varies by plan. HSA and FSA accounts are accepted. Compounded medications, when required for a hyperbolic taper, are usually paid out of pocket; some compounding pharmacies offer modest cost reductions for cash patients.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented should not be used to diagnose or treat any medical condition without consultation with a qualified clinician. Antidepressant tapering decisions require individualized clinical assessment. Do not stop or change psychiatric medications without consulting your prescribing clinician.

References

1. Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications. Psychother Psychosom. 2020;89(5):283-306. PMID: 32259826.
2. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav. 2019;97:111-121. PMID: 30292574.
3. Henssler J, Schmidt Y, Schmidt U, Schwarzer G, Bschor T, Baethge C. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. Lancet Psychiatry. 2024;11(7):526-535. PMID: 38851198. Lancet Psychiatry full text.
4. Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. Lancet Psychiatry. 2019;6(6):538-546. PMID: 30850328.
5. Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs. Wiley-Blackwell; 2024. ISBN 978-1-119-82298-1.
6. National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222). NICE; 2022. NICE NG222.
7. Royal College of Psychiatrists. Position statement on antidepressants and depression (PS04/19). RCPsych; 2019. RCPsych PS04/19.
8. US Food and Drug Administration. Paxil (paroxetine) tablets and oral suspension prescribing information (via DailyMed, Apotex Corp.). Label version effective October 2024. DailyMed label.
9. US Food and Drug Administration. Effexor XR (venlafaxine extended-release capsules) prescribing information (via DailyMed, Viatris Specialty LLC). Label version effective August 2023. DailyMed label.
10. US Food and Drug Administration. Celexa (citalopram) prescribing information (via DailyMed, Allergan). Label version effective October 2023. DailyMed label.
11. US Food and Drug Administration. Lexapro (escitalopram) prescribing information (via DailyMed, Allergan). Label version effective October 2023. DailyMed label.
12. US Food and Drug Administration. Zoloft (sertraline) prescribing information (via DailyMed, Viatris Specialty LLC). Label version effective August 2023. DailyMed label.